With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.109-07-9,2-Methylpiperazine,as a common compound, the synthetic route is as follows.
1-(t-Butoxycarbonyl)-3-methylpiperazine To a cold (-5° C.) solution of 2-methylpiperazine (5.00 g, 0.05 mole) in 200 mL of CH2 Cl2 under Ar was added a solution of di-t-butyl dicarbonate (10.9 g, 0.05 mole) in 100 mL of CH2 Cl2 over 1 h. The resulting mixture was stirred at -5° C. for 1 h and then at r.t. for 2 h. The solution was then washed (H2 O), dried (Na2 SO4) and evaporated to give an oil which was chromatographed (SiO2 /ethyl acetate then ethyl acetate-MeOH-NH4 OH 10:1:0.1) to give the product (4.30 g, 43percent) as an oil. This material was used without further purification: 1 H nmr (200 MHz, CDCl3) delta 4.15-3.75 (br s, 2H), 3.0-2.6 (m, 4H), 2.47-2.35 (m, 1H), 1.48 (s, 9H), 1.08 (d, J=6.7 Hz, 3H).
109-07-9, The synthetic route of 109-07-9 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; Bristol-Myers Squibb Company; US5434154; (1995); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics